Picture a patient in your clinic who tells you, flatly, that she has been thinking about not being here anymore. You have a safety plan to write, a risk formulation to document, and a question that every new prescriber eventually asks in the quiet of their own head: what can I actually offer that works fast enough?
That question sits underneath one of the more interesting stories in psychiatry this fall. In September 2026, HCPLive’s roundup of the month’s missed psychiatry headlines flagged a new secondary analysis showing that accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) eased suicidal ideation faster than standard once-daily dosing. It is not a cure, it is not a landmark, and it comes with caveats we will get to. But it is exactly the kind of finding that separates a student who memorizes drug lists from a clinician who understands where the field is heading. So let’s walk through it together.
What the study actually found
The analysis comes from a multisite randomized trial comparing an accelerated Deep TMS schedule (the trial is known as SWIFT) with the standard approach of one session per day, in adults with major depressive disorder. The researchers went back into the data and asked a narrower question than the original trial did: what happened to suicidal ideation?
According to HCPLive’s coverage, which included a Q&A with psychiatrist Owen Muir, MD, the numbers looked like this. Across 89 enrolled patients, the share reporting suicidal ideation fell from 22.5% at baseline to 6.7% at six weeks. That is roughly a 70% relative reduction. The median time to improvement in suicidal ideation was about 10 days with the accelerated schedule versus about 13 days with standard dosing, a statistically significant gap of around three days.
Three days sounds small until you think about what three days means to someone who is actively struggling. It also helps to remember why acceleration exists in the first place. A conventional TMS course is typically delivered daily over several weeks. Accelerated protocols compress multiple sessions into a single day so the course finishes sooner. The appeal for suicidal patients is obvious: if the same treatment can do its work in less calendar time, the window of highest risk gets shorter.

An earlier signal in the sickest patients
This is not the first time researchers have looked at accelerated Deep TMS in people with suicidal thinking. An exploratory, randomized, double-blind, sham-controlled pilot published in the Journal of Affective Disorders (online November 2025) enrolled 39 inpatients with major depression and active suicidality. Thirty-one completed at least nine treatment days and were included in the efficacy analysis. Participants received ten days of accelerated treatment, with three theta-burst sessions a day, using one of two H-coils or a sham coil.
Both active arms produced greater reductions on the Quick Inventory of Depressive Symptomatology than sham, and only the active group showed lower suicidal ideation intensity by day 10 on the Columbia Suicide Severity Rating Scale. Adverse events were mild and transient, and two patients discontinued. The authors called the suicidality findings a promising signal and said confirmation in larger multicenter samples is warranted.
Put the two papers side by side and you get a coherent, careful story: a small sham-controlled pilot in acutely suicidal inpatients suggesting feasibility and safety, plus a larger secondary analysis suggesting faster relief in outpatients with depression. Neither one settles the question. Together they make a reasonable hypothesis worth testing at scale.
Read it like a skeptic, because you will be graded as one
Here is where I want to slow you down, because this is the skill that matters most. A headline that says “70% reduction” is doing a lot of work, and a good PMHNP learns to ask what is underneath it.
First, this is a secondary analysis. The original trial was designed to compare depression outcomes, not suicidality. Secondary analyses generate hypotheses; they do not confirm them. Second, the sample is small, at 89 patients, and the baseline rate of suicidal ideation was modest. HCPLive’s reporting notes that the most severely suicidal patients were excluded from the trial. That is a safety-driven design choice, but it means we do not know how these results translate to the patient who walks into the emergency department tonight with a plan and intent.
Third, a drop in suicidal ideation in a depression trial may simply track the drop in depression. Dr. Muir himself points out that the paper does not explain a mechanism for an anti-suicidal effect that is separate from the general antidepressant effect. Fourth, this research involves a commercial device, and the clinician commentary in the coverage comes from someone with an interest in this treatment space. Dr. Muir is enthusiastic. He calls accelerated TMS a first-line option for acute suicidality in his own practice and suggests it may be worth considering before inpatient hospitalization. That is one expert’s clinical opinion, and he acknowledges that larger real-world data are needed. It is not a guideline.
When you read industry-adjacent research, hold two thoughts at once: the data can be genuinely promising, and the people closest to the product are not the right people to tell you how far to trust it. Look for independent replication. Look for the comparison arm. Look at who was left out.

Where this fits in what you already know
You are probably already tracking a few related threads from your coursework. The FDA has cleared TMS devices for treatment-resistant depression for years, and the Deep TMS H-coil has its own clearance history. Esketamine nasal spray carries an FDA indication for adults with major depression who have acute suicidal ideation or behavior, which makes it one of the few treatments with that specific label. Lithium has decades of evidence for reducing suicide risk in mood disorders. Clozapine has the strongest evidence in schizophrenia for reducing suicidal behavior. And ECT remains the most effective acute option we have for severe, life-threatening depression.
Accelerated TMS is trying to claim a slot on that list: a noninvasive, non-sedating option with minimal systemic side effects and a short course. The trick is that “trying to claim a slot” is not the same as “has earned it.” Treat it as an emerging option, not a replacement for the safety fundamentals.
And those fundamentals do not change. Acute suicide risk still calls for structured assessment, means-restriction counseling, a collaborative safety plan, and a clear decision about the level of care. A neuromodulation course does not substitute for any of it. If anything, a patient who is receiving several sessions in a single day needs reliable follow-up so that nobody falls through the cracks between appointments.
Why this matters for you as a PMHNP student
It sharpens your risk assessment vocabulary. You will see tools like the Columbia Suicide Severity Rating Scale (C-SSRS) used as outcome measures in these trials. If you have only seen it as a screening form, notice how researchers use it to track change over time. That is also how you can use it in practice: not just once at intake, but repeatedly, so you can see whether treatment is moving the needle.
It teaches you to think about time-to-response. In most of your pharmacology coursework, the lesson is “SSRIs take four to six weeks.” But for a patient with suicidal thoughts, speed is clinically meaningful in its own right. Expect exam questions and real-life case discussions that ask you to pick the intervention with the fastest credible onset when risk is high, and to explain why.
It reminds you that safety screening is part of the prescription. TMS has contraindications and precautions, most notably around seizure risk and certain metal implants, and screening matters. The point is not to memorize every device detail today. The point is to build the habit of asking, before you recommend any intervention, who this is not appropriate for.
It prepares you for the access conversation. Dr. Muir noted that many inpatient units lack access to accelerated TMS because of how services are paid for. Whether you end up in private practice, a community agency, or a hospital system, you will run into the gap between what the evidence suggests and what a given setting can deliver. Knowing the evidence is step one. Knowing how to advocate, refer, and coordinate is step two. Depending on your state and your practice setting, you may be the person who recognizes that a patient is a good candidate and gets them to a TMS provider quickly.
It gives you practice with honest uncertainty. This might be the most important one. The best clinicians I know are comfortable saying, “Here is what the data suggest, here is what we do not know yet, and here is what I would do while we wait.” You can practice that sentence on this study.
A quick study framework you can reuse
Whenever a new treatment headline lands in your feed, run it through five questions. What was the design: randomized, sham-controlled, or a secondary analysis? How big was the sample, and who was excluded? What was the outcome, and was it the one the trial was built to test? Who funded or benefits from the finding? And has anyone independent replicated it? Apply that to accelerated TMS and suicidal ideation, and you land in a sensible place: encouraging signal, small samples, replication needed, worth knowing about.
The takeaway
Accelerated Deep TMS is not going to rewrite your suicide-prevention playbook this semester. What it might do is expand the set of options your future patients have, and it is a good reminder that psychiatry is moving toward treatments that are faster, more targeted, and less dependent on waiting weeks to find out whether something works.
For you, the value is in the habit. Keep reading the primary sources. Keep asking who was excluded. Keep one foot in the evidence and the other in the room with the patient. That combination is what makes a PMHNP trustworthy, and it is what the board exam, in its own clumsy way, is trying to measure.
If you are in the thick of studying and want a structured way to turn headlines like this into points on exam day, I would love to help. Head over to PMHNPReview.org for board prep built for people who are serious about becoming the clinician their patients need. You are closer than you think, so keep going.
Sources: HCPLive, “5 Psychiatry Headlines You Missed in September 2026” and Q&A with Owen Muir, MD, on accelerated TMS and suicidal ideation; The Carlat Psychiatry Report, September 2026 issue (for context on current treatment coverage); an exploratory randomized, double-blind trial of accelerated deep TMS for patients with suicidal thoughts and behaviors, Journal of Affective Disorders, 2026. This article is educational and is not clinical advice.
